Decreased cortical FADD protein is associated with clinical dementia and cognitive decline in an elderly community sample

Background: FADD (Fas-associated death domain) adaptor is a crucial protein involved in the induction of cell death but also mediates non-apoptotic actions via a phosphorylated form (p-Ser194-FADD). This study investigated the possible association of FADD forms with age-related neuropathologies, cog...

ver descrição completa

Detalhes bibliográficos
Autores: Ramos-Miguel, Alfredo, Garcia-Sevilla, Jesus A., Barr, Alasdair M., Bayer, Thomas A., Falkai, Peter, Leurgans, Sue E., Schneider, Julie A., Bennett, David A., Honer, William G., García-Fuster, M Julia
Formato: artículo
Fecha de publicación:2017
País:España
Recursos:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/9901
Acesso em linha:https://hdl.handle.net/20.500.13003/9901
Access Level:acceso abierto
Palavra-chave:Blotting, Western
Mice
Fas-Associated Death Domain Protein
Animals
Female
Biomarkers
Male
Fluorescent Antibody Technique
Mice, Transgenic
Cognitive Dysfunction
Humans
Aged, 80 and over
Prefrontal Cortex
Anciano de 80 o más Años
Ratones Transgénicos
Corteza Prefrontal
Disfunción Cognitiva
Ratones
Humanos
Western Blotting
Proteína de Dominio de Muerte Asociada a Fas
Animales
Biomarcadores
Femenino
Técnica del Anticuerpo Fluorescente
Masculino
Alzheimer's disease
Aging
Neurotoxicity
Neuroplasticity
Apoptosis
Descrição
Resumo:Background: FADD (Fas-associated death domain) adaptor is a crucial protein involved in the induction of cell death but also mediates non-apoptotic actions via a phosphorylated form (p-Ser194-FADD). This study investigated the possible association of FADD forms with age-related neuropathologies, cognitive function, and the odds of dementia in an elderly community sample. Methods: FADD forms were quantified by western blot analysis in dorsolateral prefrontal cortex (DLPFC) samples from a large cohort of participants in a community-based aging study (Memory and Aging Project, MAP), experiencing no-(NCI, n = 51) or mild-(MCI, n = 42) cognitive impairment, or dementia (n = 57). Results: Cortical FADD was lower in subjects with dementia and lower FADD was associated with a greater load of amyloid-beta pathology, fewer presynaptic terminal markers, poorer cognitive function and increased odds of dementia. Together with the observations of FADD redistribution into tangles and dystrophic neurites within plaques in Alzheimer's disease brains, and its reduction in APP23 mouse cortex, the results suggest this multifunctional protein might participate in the mechanisms linking amyloid and tau pathologies during the course of the illness. Conclusions: The present data suggests FADD as a putative biomarker for pathological processes associated with the course of clinical dementia.